0001558370-23-017308.txt : 20231102 0001558370-23-017308.hdr.sgml : 20231102 20231102063512 ACCESSION NUMBER: 0001558370-23-017308 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231102 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ImmunoGen, Inc. CENTRAL INDEX KEY: 0000855654 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042726691 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-17999 FILM NUMBER: 231369923 BUSINESS ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781)895-0600 MAIL ADDRESS: STREET 1: 830 WINTER ST CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOGEN INC DATE OF NAME CHANGE: 19920703 8-K 1 imgn-20231102x8k.htm 8-K
0000855654false00008556542023-11-022023-11-02

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 2, 2023

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

Massachusetts

0-17999

04-2726691

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

830 Winter Street, Waltham, MA 02451

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (781) 895-0600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

    

Trading Symbol

    

Name of Each Exchange on Which Registered

Common Stock, $.01 par value

IMGN

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

ITEM 2.02 – RESULTS OF OPERATION AND FINANCIAL CONDITION

On November 2, 2023, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release to announce the Company’s financial results for the quarter and nine months ended September 30, 2023. The press release announcing financial results for the quarter and nine months ended September 30, 2023 is included as Exhibit 99.1 and incorporated herein by reference.

ITEM 9.01 Financial Statements and Exhibits.

(d): Exhibits

Exhibit No.

    

Exhibit

99.1

Press Release of ImmunoGen, Inc. dated November 2, 2023

104

Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ImmunoGen, Inc.

(Registrant)

Date: November 2, 2023

/s/ Renee Lentini

Renee Lentini

Vice President - Finance, Chief Accounting Officer (Principal Accounting Officer)

EX-99.1 2 imgn-20231102xex99d1.htm EX-99.1

Exhibit 99.1

ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results

Continued Strong Demand for ELAHERE; US Net Sales of $105.2 Million in Q3

ELAHERE MAA in FRα-Positive Platinum-Resistant Ovarian Cancer Accepted by EMA; sBLA to Support Full Approval in US Submitted to FDA

PICCOLO Trial of ELAHERE in Platinum-Sensitive Ovarian Cancer Meets Primary Endpoint of Objective Response Rate; Full Data Anticipated in Mid-2024

Advanced Geographic Market Expansion Through Collaboration with Takeda to Develop and Commercialize ELAHERE in Japan and Acceptance of NDA by the NMPA in China

Expanded Leadership Team with Appointments of Lauren White, Chief Financial Officer, and Heather Adkins Huet, Chief Scientific Officer

Conference Call to be Held at 8:00 a.m. ET Today

Waltham, MA – November 2, 2023 - ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023.

“Building on the momentum generated in the first half of 2023, we delivered a strong third quarter highlighted by significant ELAHERE revenue growth and the achievement of key operational milestones,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer. “With a 36% increase in sequential quarterly net sales and over $210 million in product revenue through the first nine months of the year, ELAHERE is tracking towards one of the most successful first product launches in oncology in a decade. We also made important progress in our effort to bring ELAHERE to eligible patients around the world with the acceptance of the MAA by the EMA and the NDA by the NMPA, and the establishment of a collaboration with Takeda to deliver ELAHERE in Japan.”

Enyedy continued, “In addition, we advanced the ELAHERE development program and are pleased to report that our PICCOLO trial in platinum-sensitive ovarian cancer has met the primary endpoint of objective response rate based on an interim efficacy assessment. With a number of patients remaining on treatment and longer follow-up required to establish mature response durability of ELAHERE in this patient population, we anticipate an ORR of at least 48% when we report full data in mid-2024. Turning to our second pivotal program, PVEK, we continue to advance our 802 study and look forward to reporting data from our PVEK/VEN/AZA triplet in frontline AML at ASH in December. We also continued to monitor the NSCLC cohort with IMGC936 and advanced dose escalation with IMGN151, our second-generation ADC targeting FRα. We look forward to a strong finish to the year and a productive 2024 with the continued growth of ELAHERE, important new data for our programs, and geographic expansion in Europe and China.”

RECENT PROGRESS

ELAHERE (mirvetuximab soravtansine-gynx)

Generated $105.2 million in ELAHERE net sales for the quarter ended September 30, 2023.
Obtained acceptance of the Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for ELAHERE in folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) to support approval and launch in Europe.
Submitted the supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) to support conversion to full approval.

Our partner, Huadong Medicine, obtained acceptance of the New Drug Application (NDA) to the National Medical Products Administration (NMPA) of China for ELAHERE in FRα-positive PROC to support approval and launch.
Announced collaboration with Takeda Pharmaceutical Company Limited (Takeda) granting Takeda an exclusive license to develop and commercialize ELAHERE in Japan. The Company received an upfront payment of $23.21 million and is eligible to receive up to approximately $1352 million in regulatory and commercial milestone payments in addition to tiered royalties in the low double-digits to mid-twenties.

Clinical Pipeline and Research

Presented additional subset analyses in prior lines of therapy and prior exposure to PARP inhibitor (PARPi) therapy from MIRASOL in an oral session at the 24th Congress of the European Society of Gynaecological Oncology (ESGO) demonstrating clinical outcomes of safety and efficacy consistent with the overall MIRASOL study population.
Reported that PICCOLO, the ongoing single-arm Phase 2 trial of mirvetuximab in FRα-high, platinum-sensitive ovarian cancer (PSOC) has met the primary endpoint of objective response rate (ORR) based upon an interim assessment with no new safety signals identified. An ORR of at least 48% is expected when full data are reported in mid-2024.
Established a multi-target license and option agreement with ImmunoBiochem Corporation to develop next-generation ADCs.

Corporate

Appointed Lauren White as Senior Vice President and Chief Financial Officer, and Heather Adkins Huet, PhD, as Senior Vice President and Chief Scientific Officer.

ANTICIPATED UPCOMING EVENTS

Potential FDA approval of ELAHERE’s sBLA in H1 2024.
Report full data from the single-arm Phase 2 PICCOLO trial of mirvetuximab in FRα-high PSOC in mid-2024.
Potential EMA approval of ELAHERE in late 2024 to support launch in Europe.
Our partner, Huadong Medicine, is planning for NMPA approval of ELAHERE by the end of 2024 to support launch in China.
Report data from the 802 trial, evaluating the pivekimab sunirine (pivekimab) triplet with Venclexta® (venetoclax) and Vidaza® (azacitidine) in frontline acute myeloid leukemia (AML) at the American Society of Hematology (ASH) Annual Meeting in December 2023.
Report top-line data from the pivotal frontline de novo cohort in the Phase 2 CADENZA trial of pivekimab in blastic plasmacytoid dendritic cell neoplasm (BPDCN) in 2024.
Provide an update on the IMGC936 non-small cell lung cancer (NSCLC) cohort following a prespecified interim analysis.

FINANCIAL RESULTS

Total revenues were $113.4 million for the quarter ended September 30, 2023, including $105.2 million of net product revenues from sales of ELAHERE, compared to $15.4 million in total revenues for the quarter ended September 30, 2022. The increase was driven by ELAHERE net sales, partially offset by $7.4 million of license fees recorded as revenue in the prior year period pursuant to the Company’s collaboration agreements with Eli Lilly and Company and Novartis Institutes for BioMedical Research, Inc.

Research and development expenses were $47.6 million for the quarter ended September 30, 2023 compared to $59.2 million for the quarter ended September 30, 2022. The decrease was primarily driven by ELAHERE supply costs expensed in the prior quarter versus capitalized in the current period and lower hiring expenses. Partially offsetting these decreases, salaries and benefits increased driven largely by the expansion of our medical affairs organization.

Selling, general and administrative expenses were $37.7 million for the quarter ended September 30, 2023 compared to $33.6 million for the quarter ended September 30, 2022. The increase was due primarily to greater expenses in support of the US launch of ELAHERE, including costs related to the addition of our commercial organization and sales and marketing activities.


Net income for the third quarter of 2023 was $30.7 million, or $0.10 per basic and diluted share, compared to a net loss of $77.8 million, or $0.31 per basic and diluted share, for the third quarter of 2022.

ImmunoGen had $605.5 million in cash and cash equivalents and $130.7 million in accounts receivable as of September 30, 2023, compared with $275.1 million in cash and cash equivalents and $12.6 million in accounts receivable as of December 31, 2022. Cash used in operations was $137.7 million for the first nine months of 2023 compared with cash used in operations of $169.6 million for the same period in 2022. Capital expenditures were $1.6 million and $1.1 million for the first nine months of 2023 and 2022, respectively.

FINANCIAL GUIDANCE

ImmunoGen’s full year financial guidance for 2023 remains unchanged; the Company continues to expect:

revenues, excluding product revenue from ELAHERE, between $45 million and $50 million; and
operating expenses between $350 million and $365 million.

The Company continues to expect that its existing cash and cash equivalents, together with anticipated future product and collaboration revenues, will fund operations for more than two years.

CONFERENCE CALL INFORMATION

ImmunoGen will hold a conference call today at 8:00 a.m. ET to discuss these results. To access the live call by phone, please register here. A dial-in and unique PIN will be provided to join the call. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com. Following the call, a replay will be available at the same location.

ABOUT ELAHERE
ELAHERE® (mirvetuximab soravtansine-gynx) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells.

ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Eye problems are common with ELAHERE and can be severe. ELAHERE also can cause severe or life-threatening inflammation of the lungs that may lead to death and patients may develop nerve problems called peripheral neuropathy during treatment. Please see full Prescribing Information, including Boxed Warning, and Medication Guide for ELAHERE.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.

Vidaza® and Venclexta® are registered trademarks of their respective owners. ELAHERE® is a registered trademark of ImmunoGen, Inc.

1 ¥3.4 billion (0.0068 exchange rate as of September 5, 2023); 2 ¥19.9 billion (0.0068 exchange rate as of August 25, 2023)


FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. These statements include, but are not limited to, the timing and outcome of the submissions of a Marketing Authorization Application in Europe, a supplemental Biologics License Application in the US, and a New Drug Application in China; the potential development and commercialization of ELAHERE in Japan; the timing and presentation of clinical data on the Company’s products and product candidates, including data from the PICCOLO trial, the pivekimab triplet, top-line data from the Phase 2 CADENZA trial, and IMGC936; the Company’s revenues and operating expenses for 2023; the Company’s anticipated cash runway; and the Company’s future product and collaboration revenues. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the successful execution of the collaboration with Takeda and their development and commercialization efforts; the timing and outcome of the Company's clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of clinical trials and regulatory processes; the timing and outcome of anticipated interactions with regulatory authorities; the risk that the Company may not be able to obtain adequate price and reimbursement for any approved products, including the potential for delays or additional difficulties for ELAHERE in light of the FDA granting accelerated approval; and other factors as set forth in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2023, the Company's Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission on April 28, 2023 and July 31, 2023, and other reports filed with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this press release. ImmunoGen undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by applicable law.

INVESTOR RELATIONS CONTACT

ImmunoGen

Anabel Chan

781-895-0600

anabel.chan@immunogen.com

MEDIA CONTACTS

ImmunoGen

Courtney O’Konek

781-895-0600

courtney.okonek@immunogen.com

OR

FTI Consulting

Robert Stanislaro

212-850-5657

robert.stanislaro@fticonsulting.com


SELECTED FINANCIAL INFORMATION

(in thousands, except per share amounts)

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

September 30,

December 31,

2023

2022

ASSETS

Cash and cash equivalents

$

605,535

$

275,138

Accounts receivable

130,694

12,596

Inventory

33,768

16,196

Other assets

52,104

45,006

Total assets

$

822,101

$

348,936

LIABILITIES AND SHAREHOLDERS' EQUITY

Current portion of deferred revenue

$

37,186

$

13,856

Other current liabilities

97,474

108,002

Term loan, net

72,113

-

Long-term portion of deferred revenue

26,718

36,355

Other long-term liabilities

27,014

34,897

Shareholders' equity

561,596

155,826

Total liabilities and shareholders' equity

$

822,101

$

348,936


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2023

2022

2023

2022

Revenues:

Product revenue, net

$

105,164

$

-

$

212,079

$

-

License and milestone fees

51

7,382

15,122

45,247

Non-cash royalty revenue

7,355

7,993

17,936

21,537

Research and development support

855

-

1,310

831

Total revenues

113,425

15,375

246,447

67,615

Cost and operating expenses:

Cost of sales

2,155

-

3,690

-

Research and development

47,570

59,181

149,267

154,885

Selling, general and administrative

37,744

33,623

114,116

74,064

Total cost and operating expenses

87,469

92,804

267,073

228,949

Interest income (expense), net

4,844

1,539

8,918

2,183

Non-cash interest expense on liability related to sale of future royalties and term loan

(1,054)

(867)

(2,986)

(3,194)

Other loss, net

(164)

(998)

(109)

(1,576)

Income (loss) before income taxes

$

29,582

$

(77,755)

$

(14,803)

$

(163,921)

Income tax benefit

1,166

-

289

-

Net income (loss)

$

30,748

$

(77,755)

$

(14,514)

$

(163,921)

Net income (loss) per common share - basic

$

0.10

$

(0.31)

$

(0.05)

$

(0.65)

Net income (loss) per common share - diluted

$

0.10

$

(0.31)

$

(0.05)

$

(0.65)

Weighted average common shares outstanding - basic

273,341

253,511

265,265

253,371

Weighted average common shares outstanding - diluted

287,590

253,511

265,265

253,371


EX-101.SCH 3 imgn-20231102.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 imgn-20231102_def.xml EX-101.DEF EX-101.LAB 5 imgn-20231102_lab.xml EX-101.LAB EX-101.PRE 6 imgn-20231102_pre.xml EX-101.PRE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 02, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 02, 2023
Securities Act File Number 0-17999
Entity Registrant Name ImmunoGen, Inc.
Entity Incorporation, State or Country Code MA
Entity Tax Identification Number 04-2726691
Entity Address, Address Line One Massachusetts
Entity Address, State or Province MA
Entity Address, City or Town Waltham
Entity Address, Postal Zip Code 02451
City Area Code 781
Local Phone Number 895-0600
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $.01 par value
Trading Symbol IMGN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0000855654
Amendment Flag false
XML 8 R2.htm IDEA: XBRL DOCUMENT v3.23.3
N-2
Nov. 02, 2023
Cover [Abstract]  
Entity Central Index Key 0000855654
Amendment Flag false
Securities Act File Number 0-17999
Document Type 8-K
Entity Registrant Name ImmunoGen, Inc.
Entity Address, Address Line One Massachusetts
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code 781
Local Phone Number 895-0600
Entity Emerging Growth Company false
XML 9 imgn-20231102x8k_htm.xml IDEA: XBRL DOCUMENT 0000855654 2023-11-02 2023-11-02 0000855654 false 8-K 2023-11-02 ImmunoGen, Inc. Massachusetts MA 0-17999 04-2726691 Waltham MA 02451 781 895-0600 false false false false Common Stock, $.01 par value IMGN NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

"'4 $ M ,4" / " 983 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 M " !E-&)7C?&PO7W)E M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !E-&)7;J XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.immunogen.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995470 - Disclosure - N-2 Sheet http://xbrl.sec.gov/cef/role/N2 N-2 Notes 2 false false All Reports Book All Reports imgn-20231102.xsd imgn-20231102_def.xml imgn-20231102_lab.xml imgn-20231102_pre.xml imgn-20231102x8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "imgn-20231102x8k.htm": { "nsprefix": "imgn", "nsuri": "http://www.immunogen.com/20231102", "dts": { "schema": { "local": [ "imgn-20231102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/2006/xbrldi-2006.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/cef/2023/cef-2023.xsd", "https://xbrl.sec.gov/cef/2023/cef-2023_pre.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023_lab.xsd" ] }, "definitionLink": { "local": [ "imgn-20231102_def.xml" ] }, "labelLink": { "local": [ "imgn-20231102_lab.xml" ] }, "presentationLink": { "local": [ "imgn-20231102_pre.xml" ] }, "inline": { "local": [ "imgn-20231102x8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 207, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_11_2_2023_To_11_2_2023_Vhqk44OISUmfyULPxupRzg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "imgn-20231102x8k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_11_2_2023_To_11_2_2023_Vhqk44OISUmfyULPxupRzg", "name": "dei:DocumentPeriodEndDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "imgn-20231102x8k.htm", "unique": true } }, "R2": { "role": "http://xbrl.sec.gov/cef/role/N2", "longName": "995470 - Disclosure - N-2", "shortName": "N-2", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "2", "firstAnchor": { "contextRef": "Duration_11_2_2023_To_11_2_2023_Vhqk44OISUmfyULPxupRzg", "name": "dei:EntityFileNumber", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "imgn-20231102x8k.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "cef_SeniorSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities [Table Text Block]" } } }, "auth_ref": [] }, "cef_AnnualDividendPaymentInitial": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualDividendPaymentInitial", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Initial" } } }, "auth_ref": [] }, "cef_OtherMasterFundExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherMasterFundExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Master Fund Expenses [Percent]" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "cef_OtherAnnualExpense1Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpense1Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expense 1 [Percent]" } } }, "auth_ref": [] }, "cef_ExpenseExampleYears1to5": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYears1to5", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 5" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesCoveragePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesCoveragePerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Coverage per Unit (Deprecated 2023-01-31)" } } }, "auth_ref": [] }, "dei_InvestmentCompanyActFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyActFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Act File Number" } } }, "auth_ref": [ "r10", "r11", "r12", "r13" ] }, "cef_RiskTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RiskTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk [Text Block]" } } }, "auth_ref": [] }, "cef_ExpenseExampleYears1to3": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYears1to3", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 3" } } }, "auth_ref": [] }, "cef_ExpenseExampleYears1to10": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYears1to10", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Years 1 to 10" } } }, "auth_ref": [] }, "dei_InvestmentCompanyRegistrationAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyRegistrationAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment Number" } } }, "auth_ref": [ "r15" ] }, "cef_SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesInvoluntaryLiquidatingPreferencePerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Involuntary Liquidating Preference per Unit (Deprecated 2023-01-31)" } } }, "auth_ref": [] }, "cef_OtherFeederFundExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherFeederFundExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Feeder Fund Expenses [Percent]" } } }, "auth_ref": [] }, "dei_PreEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment" } } }, "auth_ref": [ "r0" ] }, "cef_SeniorSecuritiesHighlightsAnnualizedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesHighlightsAnnualizedNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Annualized, Note [Text Block]" } } }, "auth_ref": [] }, "cef_PurposeOfFeeTableNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PurposeOfFeeTableNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Purpose of Fee Table , Note [Text Block]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities, Note [Text Block]" } } }, "auth_ref": [] }, "dei_InvestmentCompanyRegistrationAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyRegistrationAmendment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Registration Amendment" } } }, "auth_ref": [ "r15" ] }, "cef_DividendExpenseOnPreferredSharesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DividendExpenseOnPreferredSharesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend Expenses on Preferred Shares [Percent]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesAverageMarketValuePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesAverageMarketValuePerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Average Market Value per Unit" } } }, "auth_ref": [] }, "cef_ManagementFeeNotBasedOnNetAssetsNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ManagementFeeNotBasedOnNetAssetsNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Management Fee not based on Net Assets, Note [Text Block]" } } }, "auth_ref": [] }, "cef_OtherAnnualExpense2Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpense2Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expense 2 [Percent]" } } }, "auth_ref": [] }, "cef_BasisOfTransactionFeesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "BasisOfTransactionFeesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Basis of Transaction Fees, Note [Text Block]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesHeadingsNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesHeadingsNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Headings, Note [Text Block]" } } }, "auth_ref": [] }, "cef_OtherAnnualExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpensesAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Abstract]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesAveragingMethodNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesAveragingMethodNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Averaging Method, Note [Text Block]" } } }, "auth_ref": [] }, "cef_IncentiveAllocationMinimumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveAllocationMinimumPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Allocation Minimum [Percent]" } } }, "auth_ref": [] }, "cef_OtherTransactionFeesBasisNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesBasisNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Note [Text Block]" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "cef_SeniorSecuritiesHighlightsAuditedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesHighlightsAuditedNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Highlights Audited, Note [Text Block]" } } }, "auth_ref": [] }, "dei_EffectiveOnDate486b": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnDate486b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(b)" } } }, "auth_ref": [ "r25" ] }, "cef_GeneralDescriptionOfRegistrantAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "GeneralDescriptionOfRegistrantAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "General Description of Registrant [Abstract]" } } }, "auth_ref": [] }, "cef_OtherTransactionFeesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees, Note [Text Block]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "cef_InvestmentObjectivesAndPracticesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "InvestmentObjectivesAndPracticesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Objectives and Practices [Text Block]" } } }, "auth_ref": [] }, "dei_PreEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Pre-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective." } } }, "auth_ref": [ "r0" ] }, "cef_RiskFactorsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RiskFactorsTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk Factors [Table Text Block]" } } }, "auth_ref": [] }, "cef_OtherTransactionFeesBasisMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesBasisMaximum", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum" } } }, "auth_ref": [] }, "cef_OtherAnnualExpense3Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpense3Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": "cef_OtherAnnualExpensesPercent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expense 3 [Percent]" } } }, "auth_ref": [] }, "cef_OtherTransactionFeesBasisMaximumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionFeesBasisMaximumPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Fees Basis, Maximum [Percent]" } } }, "auth_ref": [] }, "cef_OtherExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherExpensesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Expenses, Note [Text Block]" } } }, "auth_ref": [] }, "cef_AllRisksMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AllRisksMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "All Risks:" } } }, "auth_ref": [] }, "cef_RiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RiskAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Risk [Axis]" } } }, "auth_ref": [] }, "cef_OtherAnnualExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherAnnualExpensesPercent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Ae": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Annual Expenses [Percent]" } } }, "auth_ref": [] }, "cef_HighestPriceOrBid": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "HighestPriceOrBid", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Highest Price or Bid" } } }, "auth_ref": [] }, "cef_AcquiredFundFeesEstimatedNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundFeesEstimatedNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees Estimated, Note [Text Block]" } } }, "auth_ref": [] }, "cef_AnnualDividendPayment": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualDividendPayment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment" } } }, "auth_ref": [] }, "cef_AcquiredFundFeesAndExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundFeesAndExpensesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses, Note [Text Block]" } } }, "auth_ref": [] }, "cef_SeniorSecuritiesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesAmount", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Amount (Deprecated 2023-01-31)" } } }, "auth_ref": [] }, "cef_AcquiredFundIncentiveAllocationNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundIncentiveAllocationNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Incentive Allocation, Note [Text Block]" } } }, "auth_ref": [] }, "cef_EffectsOfLeverageTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "EffectsOfLeverageTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Text Block]" } } }, "auth_ref": [] }, "cef_NetExpenseOverAssetsPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "NetExpenseOverAssetsPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Net Expense over Assets [Percent]" } } }, "auth_ref": [] }, "us-gaap_InterestRateRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestRateRiskMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Interest Rate Risk [Member]" } } }, "auth_ref": [] }, "cef_IncentiveAllocationPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveAllocationPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Allocation [Percent]" } } }, "auth_ref": [] }, "dei_PostEffectiveAmendmentNumber": { "xbrltype": "sequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PostEffectiveAmendmentNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment Number", "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective." } } }, "auth_ref": [ "r0" ] }, "dei_InvestmentCompanyActRegistration": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "InvestmentCompanyActRegistration", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Investment Company Act Registration" } } }, "auth_ref": [ "r15" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "auth_ref": [] }, "cef_WaiversAndReimbursementsOfFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WaiversAndReimbursementsOfFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Waivers and Reimbursements of Fees [Percent]" } } }, "auth_ref": [] }, "cef_AcquiredFundTotalAnnualExpensesNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundTotalAnnualExpensesNoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Total Annual Expenses, Note [Text Block]" } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "cef_IncentiveAllocationMaximumPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveAllocationMaximumPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Allocation Maximum [Percent]" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "cef_AnnualDividendPaymentCurrent": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualDividendPaymentCurrent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Dividend Payment, Current" } } }, "auth_ref": [] }, "cef_ExpenseExampleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example [Table Text Block]" } } }, "auth_ref": [] }, "cef_FinancialHighlightsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "FinancialHighlightsAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Financial Highlights [Abstract]" } } }, "auth_ref": [] }, "cef_ReturnAtPlusTenPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtPlusTenPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Plus Ten [Percent]" } } }, "auth_ref": [] }, "cef_TotalAnnualExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "TotalAnnualExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Total Annual Expenses [Percent]" } } }, "auth_ref": [] }, "dei_EffectiveAfter60Days486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveAfter60Days486a", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective after 60 Days, 486(a)" } } }, "auth_ref": [ "r24" ] }, "cef_SeniorSecuritiesAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Amount" } } }, "auth_ref": [] }, "cef_AcquiredFundFeesAndExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AcquiredFundFeesAndExpensesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Acquired Fund Fees and Expenses [Percent]" } } }, "auth_ref": [] }, "dei_EffectiveWhenDeclaredSection8c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveWhenDeclaredSection8c", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective when Declared, Section 8(c)" } } }, "auth_ref": [ "r27" ] }, "cef_LowestPriceOrBid": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LowestPriceOrBid", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid" } } }, "auth_ref": [] }, "dei_EffectiveUponFiling462e": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveUponFiling462e", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective Upon Filing, 462(e)" } } }, "auth_ref": [ "r23" ] }, "dei_EffectiveUponFiling486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveUponFiling486b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective upon Filing, 486(b)" } } }, "auth_ref": [ "r25" ] }, "dei_PostEffectiveAmendment": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PostEffectiveAmendment", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Post-Effective Amendment" } } }, "auth_ref": [ "r0" ] }, "cef_ExpenseExampleYear01": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ExpenseExampleYear01", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Expense Example, Year 01" } } }, "auth_ref": [] }, "dei_AdditionalSecuritiesEffective413b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecuritiesEffective413b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Additional Securities Effective, 413(b)" } } }, "auth_ref": [ "r18" ] }, "cef_SeniorSecuritiesCvgPerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SeniorSecuritiesCvgPerUnit", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Senior Securities Coverage per Unit" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "cef_LowestPriceOrBidNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LowestPriceOrBidNav", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, NAV" } } }, "auth_ref": [] }, "dei_DelayedOrContinuousOffering": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DelayedOrContinuousOffering", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Delayed or Continuous Offering" } } }, "auth_ref": [ "r9", "r10", "r14" ] }, "dei_DividendOrInterestReinvestmentPlanOnly": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DividendOrInterestReinvestmentPlanOnly", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend or Interest Reinvestment Plan Only" } } }, "auth_ref": [ "r9", "r10", "r14" ] }, "dei_EffectiveOnSetDate486b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnSetDate486b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(b)" } } }, "auth_ref": [ "r25" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r26" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ContactPersonnelName", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "cef_EffectsOfLeverageTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "EffectsOfLeverageTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effects of Leverage [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "auth_ref": [] }, "cef_ReturnAtMinusTenPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtMinusTenPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Minus Ten [Percent]" } } }, "auth_ref": [] }, "cef_BdcFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "BdcFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "BDC File Number" } } }, "auth_ref": [] }, "cef_DividendReinvestmentAndCashPurchaseFees": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DividendReinvestmentAndCashPurchaseFees", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend Reinvestment and Cash Purchase Fees" } } }, "auth_ref": [] }, "cef_OtherSecurityDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherSecurityDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Security, Description [Text Block]" } } }, "auth_ref": [] }, "cef_LongTermDebtTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Title [Text Block]" } } }, "auth_ref": [] }, "cef_HighestPriceOrBidNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "HighestPriceOrBidNav", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, NAV" } } }, "auth_ref": [] }, "cef_PrimaryShelfQualifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PrimaryShelfQualifiedFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Primary Shelf Qualified [Flag]" } } }, "auth_ref": [] }, "cef_LongTermDebtPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtPrincipal", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Principal" } } }, "auth_ref": [] }, "cef_LatestSharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LatestSharePrice", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Latest Share Price (Deprecated 2023-01-31)" } } }, "auth_ref": [] }, "cef_NewCefOrBdcRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "NewCefOrBdcRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "New CEF or BDC Registrant [Flag]" } } }, "auth_ref": [] }, "cef_HighestPriceOrBidPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "HighestPriceOrBidPremiumDiscountToNavPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Highest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "auth_ref": [] }, "cef_FeeTableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "FeeTableAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Fee Table [Abstract]" } } }, "auth_ref": [] }, "cef_SecurityTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Title [Text Block]" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "cef_LatestNav": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LatestNav", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Latest NAV (Deprecated 2023-01-31)" } } }, "auth_ref": [] }, "cef_LongTermDebtStructuringTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtStructuringTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Structuring [Text Block]" } } }, "auth_ref": [] }, "cef_SharePricesNotActualTransactionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SharePricesNotActualTransactionsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Share Prices Not Actual Transactions [Text Block]" } } }, "auth_ref": [] }, "cef_ShareholderTransactionExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ShareholderTransactionExpensesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Shareholder Transaction Expenses [Table Text Block]" } } }, "auth_ref": [] }, "cef_LowestPriceOrBidPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LowestPriceOrBidPremiumDiscountToNavPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Lowest Price or Bid, Premium (Discount) to NAV [Percent]" } } }, "auth_ref": [] }, "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": { "xbrltype": "dateOrAsapItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Approximate Date of Commencement of Proposed Sale to Public", "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings." } } }, "auth_ref": [] }, "cef_NoPublicTradingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "NoPublicTradingTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Public Trading [Text Block]" } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "cef_OtherSecurityTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherSecurityTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Security, Title [Text Block]" } } }, "auth_ref": [] }, "cef_InterestExpensesOnBorrowingsPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "InterestExpensesOnBorrowingsPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Interest Expenses on Borrowings [Percent]" } } }, "auth_ref": [] }, "cef_LongTermDebtIssuanceAndSubstitutionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtIssuanceAndSubstitutionTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Issuance and Substitution [Text Block]" } } }, "auth_ref": [] }, "cef_ReturnAtZeroPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtZeroPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Zero [Percent]" } } }, "auth_ref": [] }, "cef_LongTermDebtDividendsAndCovenantsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtDividendsAndCovenantsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Dividends and Covenants [Text Block]" } } }, "auth_ref": [] }, "cef_SalesLoadPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SalesLoadPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Sales Load [Percent]" } } }, "auth_ref": [] }, "cef_CapitalStockLongTermDebtAndOtherSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "CapitalStockLongTermDebtAndOtherSecuritiesAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Capital Stock, Long-Term Debt, and Other Securities [Abstract]" } } }, "auth_ref": [] }, "cef_LongTermDebtRightsLimitedByOtherSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtRightsLimitedByOtherSecuritiesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt, Rights Limited by Other Securities [Text Block]" } } }, "auth_ref": [] }, "cef_OtherSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherSecuritiesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Securities [Table Text Block]" } } }, "auth_ref": [] }, "cef_OtherTransactionExpense3Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpense3Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expense 3 [Percent]" } } }, "auth_ref": [] }, "cef_NoTradingHistoryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "NoTradingHistoryTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Trading History [Text Block]" } } }, "auth_ref": [] }, "cef_LatestPremiumDiscountToNavPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LatestPremiumDiscountToNavPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Latest Premium (Discount) to NAV [Percent]" } } }, "auth_ref": [] }, "cef_UnderwritersCompensationPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "UnderwritersCompensationPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Underwriters Compensation [Percent]" } } }, "auth_ref": [] }, "cef_RightsLimitedByOtherSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RightsLimitedByOtherSecuritiesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Rights Limited by Other Securities [Text Block]" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "cef_OtherTransactionExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpensesAbstract", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Abstract]" } } }, "auth_ref": [] }, "cef_ProspectusTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ProspectusTable", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Prospectus:" } } }, "auth_ref": [] }, "cef_SecurityDividendsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityDividendsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Dividends [Text Block]" } } }, "auth_ref": [] }, "cef_WarrantsOrRightsCalledPeriodDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsCalledPeriodDate", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Period [Date]" } } }, "auth_ref": [] }, "cef_OtherTransactionExpense1Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpense1Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expense 1 [Percent]" } } }, "auth_ref": [] }, "cef_WarrantsOrRightsCalledAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsCalledAmount", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Amount" } } }, "auth_ref": [] }, "cef_OtherTransactionExpense2Percent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpense2Percent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": "cef_OtherTransactionExpensesPercent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expense 2 [Percent]" } } }, "auth_ref": [] }, "cef_CapitalStockTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "CapitalStockTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Capital Stock [Table Text Block]" } } }, "auth_ref": [] }, "cef_WarrantsOrRightsCalledTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsCalledTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Called Title" } } }, "auth_ref": [] }, "dei_EntityInvCompanyType": { "xbrltype": "invCompanyType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInvCompanyType", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Inv Company Type", "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product)." } } }, "auth_ref": [ "r16" ] }, "cef_OtherTransactionExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OtherTransactionExpensesPercent", "calculation": { "http://xbrl.sec.gov/cef/role/Item3Te": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Other Transaction Expenses [Percent]" } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "BusinessContactMember", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r7", "r8" ] }, "cef_WarrantsOrRightsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "WarrantsOrRightsExercisePrice", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Warrants or Rights, Exercise Price" } } }, "auth_ref": [] }, "cef_OutstandingSecuritiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecuritiesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Securities [Table Text Block]" } } }, "auth_ref": [] }, "cef_SecurityVotingRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityVotingRightsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Voting Rights [Text Block]" } } }, "auth_ref": [] }, "cef_AnnualExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualExpensesTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Expenses [Table Text Block]" } } }, "auth_ref": [] }, "cef_OutstandingSecurityAuthorizedShares": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityAuthorizedShares", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Authorized [Shares]" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "cef_OutstandingSecurityTitleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityTitleTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Title [Text Block]" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "cef_LongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LongTermDebtTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Long Term Debt [Table Text Block]" } } }, "auth_ref": [] }, "cef_ManagementFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ManagementFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Management Fees [Percent]" } } }, "auth_ref": [] }, "cef_OutstandingSecurityNotHeldShares": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityNotHeldShares", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Not Held [Shares]" } } }, "auth_ref": [] }, "cef_OutstandingSecurityHeldShares": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "OutstandingSecurityHeldShares", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Outstanding Security, Held [Shares]" } } }, "auth_ref": [] }, "cef_ReturnAtPlusFivePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtPlusFivePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Plus Five [Percent]" } } }, "auth_ref": [] }, "cef_SecurityLiquidationRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityLiquidationRightsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Liquidation Rights [Text Block]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r19" ] }, "cef_PreferredStockRestrictionsOtherTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PreferredStockRestrictionsOtherTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Other [Text Block]" } } }, "auth_ref": [] }, "cef_ProspectusLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ProspectusLineItems", "lang": { "en-us": { "role": { "label": "Prospectus [Line Items]" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r6" ] }, "cef_DividendAndInterestExpensesOnShortSalesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DividendAndInterestExpensesOnShortSalesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Dividend and Interest Expenses on Short Sales [Percent]" } } }, "auth_ref": [] }, "cef_SecurityLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityLiabilitiesTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Liabilities [Text Block]" } } }, "auth_ref": [] }, "cef_SecurityPreemptiveAndOtherRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityPreemptiveAndOtherRightsTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Preemptive and Other Rights [Text Block]" } } }, "auth_ref": [] }, "cef_IncentiveFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IncentiveFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Incentive Fees [Percent]" } } }, "auth_ref": [] }, "cef_DistributionsMayReducePrincipalTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DistributionsMayReducePrincipalTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Distributions May Reduce Principal [Text Block]" } } }, "auth_ref": [] }, "cef_DistributionServicingFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "DistributionServicingFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Distribution/Servicing Fees [Percent]" } } }, "auth_ref": [] }, "cef_LoanServicingFeesPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "LoanServicingFeesPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Loan Servicing Fees [Percent]" } } }, "auth_ref": [] }, "cef_SecurityObligationsOfOwnershipTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SecurityObligationsOfOwnershipTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Security Obligations of Ownership [Text Block]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockLiquidationPreference": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockLiquidationPreference", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Liquidating Preference" } } }, "auth_ref": [] }, "cef_RightsSubjectToOtherThanMajorityVoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RightsSubjectToOtherThanMajorityVoteTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Rights Subject to Other than Majority Vote [Text Block]" } } }, "auth_ref": [] }, "cef_PreferredStockRestrictionsArrearageTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PreferredStockRestrictionsArrearageTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Preferred Stock Restrictions, Arrearage [Text Block]" } } }, "auth_ref": [] }, "dei_ExhibitsOnly462dFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExhibitsOnly462dFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d), File Number" } } }, "auth_ref": [ "r22" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]" } } }, "auth_ref": [] }, "cef_AnnualInterestRateCurrentPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualInterestRateCurrentPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Current [Percent]" } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Share Price" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EffectiveOnSetDate486a": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnSetDate486a", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Set Date, 486(a)" } } }, "auth_ref": [ "r24" ] }, "dei_NoSubstantiveChanges462c": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoSubstantiveChanges462c", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c)" } } }, "auth_ref": [ "r21" ] }, "cef_AnnualCoverageReturnRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualCoverageReturnRatePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Coverage Return Rate [Percent]" } } }, "auth_ref": [] }, "cef_AnnualInterestRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualInterestRatePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Interest Rate [Percent]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_NewEffectiveDateForPreviousFiling": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NewEffectiveDateForPreviousFiling", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "New Effective Date for Previous Filing" } } }, "auth_ref": [ "r10", "r11", "r12", "r13" ] }, "dei_ExhibitsOnly462d": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "ExhibitsOnly462d", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Exhibits Only, 462(d)" } } }, "auth_ref": [ "r22" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "cef_EffectsOfLeveragePurposeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "EffectsOfLeveragePurposeTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effects of Leverage, Purpose [Text Block]" } } }, "auth_ref": [] }, "dei_NoSubstantiveChanges462cFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoSubstantiveChanges462cFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "No Substantive Changes, 462(c), File Number" } } }, "auth_ref": [ "r21" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_AdditionalSecurities462bFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecurities462bFileNumber", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Additional Securities, 462(b), File Number" } } }, "auth_ref": [ "r20" ] }, "us-gaap_NetAssetValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetAssetValuePerShare", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "NAV Per Share" } } }, "auth_ref": [] }, "dei_EffectiveOnDate486a": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EffectiveOnDate486a", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Effective on Date, 486(a)" } } }, "auth_ref": [ "r24" ] }, "cef_ReturnAtMinusFivePercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "ReturnAtMinusFivePercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Return at Minus Five [Percent]" } } }, "auth_ref": [] }, "cef_PrimaryShelfFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "PrimaryShelfFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Primary Shelf [Flag]" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "cef_RegisteredClosedEndFundFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "RegisteredClosedEndFundFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Registered Closed-End Fund [Flag]" } } }, "auth_ref": [] }, "cef_BusinessDevelopmentCompanyFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "BusinessDevelopmentCompanyFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Business Development Company [Flag]" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r3" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_AdditionalSecurities462b": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AdditionalSecurities462b", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Additional Securities. 462(b)" } } }, "auth_ref": [ "r20" ] }, "cef_SharePriceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "SharePriceTableTextBlock", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Share Price [Table Text Block]" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation", "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.immunogen.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "cef_AnnualInterestRateInitialPercent": { "xbrltype": "percentItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "AnnualInterestRateInitialPercent", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Annual Interest Rate, Initial [Percent]" } } }, "auth_ref": [] }, "cef_IntervalFundFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cef/2023", "localname": "IntervalFundFlag", "presentation": [ "http://xbrl.sec.gov/cef/role/N2" ], "lang": { "en-us": { "role": { "label": "Interval Fund [Flag]" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form F-3" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-2" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-3" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-4" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-6" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form S-3" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Investment Company Act", "Number": "270" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "313" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "413", "Subsection": "b" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r20": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "b" }, "r21": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "c" }, "r22": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "d" }, "r23": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "462", "Subsection": "e" }, "r24": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "a" }, "r25": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "486", "Subsection": "b" }, "r26": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r27": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Section": "8", "Subsection": "c" } } } ZIP 16 0001558370-23-017308-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-23-017308-xbrl.zip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�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end